Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events
- Author
- ARCA, Marcello1 ; GASPARDONE, Achille2
[1] Department of Clinical and Therapeutic Medicine, La Sapienza University of Rome, Rome, Italy
[2] Cardiology Department, Ospedale S. Eugenio, Rome, Italy - Issue title
- Atorvastatin in the management of cardiovascular risk: From pharmacology to clinical evidence
- Author (monograph)
- GRUNDY, Scott (Editor)1
[1] UT Southwestern Medical Center at Dallas, Dallas, Texas, United States - Source
Drugs (Basel). 2007, Vol 67, pp 29-42, 14 p ; SUP1 ; ref : 36 ref
- CODEN
- DRUGAY
- ISSN
- 0012-6667
- Scientific domain
- Pharmacology drugs
- Publisher
- Adis International, Auckland
- Publication country
- New Zealand
- Document type
- Article
- Language
- English
- Keyword (fr)
- Article synthèse Atorvastatine Efficacité traitement Homme Hypocholestérolémiant Hypolipémiant Pathologie de l'appareil circulatoire Primaire Prévention Secondaire Dérivé de la statine Enzyme Hydroxymethylglutaryl-CoA reductase Inhibiteur de l'HMG-CoA reductase Inhibiteur enzyme Oxidoreductases
- Keyword (en)
- Review Atorvastatin Treatment efficiency Human Hypocholesterolemic agent Antilipemic agent Cardiovascular disease Primary Prevention Secondary Statin derivative Enzyme Hydroxymethylglutaryl-CoA reductase HMG-CoA reductase inhibitor Enzyme inhibitor Oxidoreductases
- Keyword (es)
- Artículo síntesis Atorvastatina Eficacia tratamiento Hombre Hipocolesterolemiante Hipolipemiante Aparato circulatorio patología Primario Prevención Secundario Statina derivado Enzima Hydroxymethylglutaryl-CoA reductase Inhibidor HMG-CoA reductase Inhibidor enzima Oxidoreductases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02N General and cellular metabolism. Vitamins
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 19876989
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.2165/00003495-200767001-00004 
https://dx.doi.org/10.2165/00003495-200767001-00004
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/00003495-200767001-00004\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:86:\"Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"67\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:2:\"29\";s:8:\"\u0000*\u0000epage\";s:2:\"42\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ARCA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Marcello\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:19:\"GASPARDONE, Achille\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:93:\"Atorvastatin in the management of cardiovascular risk: From pharmacology to clinical evidence\";s:8:\"\u0000*\u0000title\";s:86:\"Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/00003495-200767001-00004\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:86:\"Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"67\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:2:\"29\";s:8:\"\u0000*\u0000epage\";s:2:\"42\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ARCA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Marcello\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:19:\"GASPARDONE, Achille\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:93:\"Atorvastatin in the management of cardiovascular risk: From pharmacology to clinical evidence\";s:8:\"\u0000*\u0000title\";s:86:\"Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/00003495-200767001-00004\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/00003495-200767001-00004\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:86:\"Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"67\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:2:\"29\";s:8:\"\u0000*\u0000epage\";s:2:\"42\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ARCA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Marcello\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:19:\"GASPARDONE, Achille\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:93:\"Atorvastatin in the management of cardiovascular risk: From pharmacology to clinical evidence\";s:8:\"\u0000*\u0000title\";s:86:\"Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/00003495-200767001-00004\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:86:\"Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"67\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:2:\"29\";s:8:\"\u0000*\u0000epage\";s:2:\"42\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ARCA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Marcello\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:19:\"GASPARDONE, Achille\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:93:\"Atorvastatin in the management of cardiovascular risk: From pharmacology to clinical evidence\";s:8:\"\u0000*\u0000title\";s:86:\"Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.2165\/00003495-200767001-00004\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:86:\"Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events\";s:9:\"\u0000*\u0000jtitle\";s:13:\"Drugs (Basel)\";s:9:\"\u0000*\u0000stitle\";s:13:\"Drugs (Basel)\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:2:\"67\";s:8:\"\u0000*\u0000issue\";s:0:\"\";s:8:\"\u0000*\u0000spage\";s:2:\"29\";s:8:\"\u0000*\u0000epage\";s:2:\"42\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0012-6667\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"ARCA\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Marcello\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:1:{i:0;s:19:\"GASPARDONE, Achille\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"DRUGAY\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:4:\"SUP1\";s:9:\"\u0000*\u0000btitle\";s:93:\"Atorvastatin in the management of cardiovascular risk: From pharmacology to clinical evidence\";s:8:\"\u0000*\u0000title\";s:86:\"Atorvastatin Efficacy in the Primary and Secondary Prevention of Cardiovascular Events\";s:8:\"\u0000*\u0000place\";s:8:\"Auckland\";s:6:\"\u0000*\u0000pub\";s:18:\"Adis International\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"14\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
